South Korea: Pharmaceutical Industry Infrastructure Overview
- Published: July 2011
The pharmaceutical industry currently represents a huge paradox. Whilst the pursuit of critical mass has driven consolidation and brought about the creation of mega-companies such as Pharmacia, GlaxoSmithKline and Pfizer, the industry as a whole and its markets remain highly fragmented. Similarly, consolidated companies have missed opportunities to re-engineer their processes, build greater brand effectiveness and, in fact, remain fragmented internally. The new report provides critical insights into the marketing and R&D implications of these key industry shifts. The report utilises an extensive survey of industry executives to pinpoint the strategic implications for industry players, providing the key data and analysis of strategies adopted by leading companies seeking to optimise both their current position and future prospects.
| Format | Properties | |
|---|---|---|
| Electronic | The report will be emailed to you. | |
| Hard Copy | A printed copy of the report will be shipped to you. |